Citi raised the firm’s price target on BioAge Labs (BIOA) to $15 from $10 and keeps a Buy rating on the shares. The firm adjusted biotech price targets as part of a Q3 earnings preview.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOA: